ResMed Bull Likes Medium-Term Margin Prospects -- Market Talk

Dow Jones
09/19

0357 GMT - ResMed's bull at Citi thinks the market is underestimating the breath-tech provider's medium-term margin-expansion capacity. Analyst Laura Sutcliffe points out that consensus for a fiscal 2026 gross margin of 62% is in-line with guidance, but ignores management's later growth ambitions. She thinks that 63% is achievable in fiscal 2027 and beyond. A good performance through fiscal 2026 could prompt analysts to rerate the stock, she writes in a note. Citi initiates coverage of ResMed's U.S.-listed stock with a US$330.00 target price and a buy rating. It also rated ResMed's Australia-listed stock a buy, and lifts its target price 4.1% to A$51.00. (stuart.condie@wsj.com)

 

(END) Dow Jones Newswires

September 18, 2025 23:57 ET (03:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10